Tier 2 — strong

Relative bioavailability of the flavonoids quercetin, hesperetin and naringenin given simultaneously through diet

K S Krogholm, L Bredsdorff, P Knuthsen, J Haraldsdóttir, S E Rasmussen
European journal of clinical nutrition 2010 64(4):432

Bibliography

PubMed
PMID 20125185
DOI
10.1038/ejcn.2010.6
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignHuman dietary flavonoid pharmacokinetic study
ModelHuman intervention research
Sample10 healthy men
InterventionA juice mixture containing equal amounts of quercetin, hesperetin, and naringenin
DurationSingle intake; plasma and urine sampling through 48 hours
EndpointsExposure and pharmacokinetics

What the study showed, in plain terms

Published in 2010, this source examined forms, absorption and food sources. Design: Human dietary flavonoid pharmacokinetic study. Sample/model: 10 healthy men. The exposure or intervention was A juice mixture containing equal amounts of quercetin, hesperetin, and naringenin. Follow-up or treatment period: Single intake; plasma and urine sampling through 48 hours.

Quercetin had much lower urinary recovery than the other flavonoids despite comparable exposure to hesperetin.

Urinary recovery alone is not a valid cross-compound measure of absorption because clearance pathways differ. Mixed juice effects are not isolated supplement effects.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Forms: Dihydrate, Phytosome, Liposomal and Glycosides. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Quercetin had much lower urinary recovery than the other flavonoids despite comparable exposure to hesperetin.
  • The recorded outcome domains were Exposure and pharmacokinetics.
  • The result applies to the tested exposure: A juice mixture containing equal amounts of quercetin, hesperetin, and naringenin; Single intake; plasma and urine sampling through 48 hours.

What this study can and cannot tell us

  • Urinary recovery alone is not a valid cross-compound measure of absorption because clearance pathways differ. Mixed juice effects are not isolated supplement effects.
  • A change in blood exposure or a metabolic marker is not a demonstrated improvement in symptoms, disease events or lifespan. The tested formulation and co-administered medicines matter.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Improving quercetin bioavailability: A systematic review and meta-analysis of human intervention studies
Lu Liu et al. · Food chemistry · 2025
Tier 2
Microbiological and Pharmacokinetic Aspects of a Water-Soluble Quercetin 3-O-rutinoside, EubioQuercetin: A Direct Comparison With Quercetin in In Vitro and Human Clinical Studies
Naoto Yamaguchi et al. · Journal of food science · 2025
Tier 2
Comparative Pharmacokinetics and Safety of a Micellar Chrysin-Quercetin-Rutin Formulation: A Randomized Crossover Trial
Afoke Ibi et al. · Antioxidants (Basel, Switzerland) · 2025
Tier 2
Enhanced Bioavailability and Pharmacokinetics of a Natural Self-Emulsifying Reversible Hybrid-Hydrogel System of Quercetin: A Randomized Double-Blinded Comparative Crossover Study
Ashil Joseph et al. · ACS omega · 2022

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology